Research conducted by Dou’s team demonstrated that isorhamnetin exerts beneficial effects on TNBS- and DSS-induced mouse inflammatory bowel disease (IBD) by upregulating xenobiotic metabolism mediated by PXR and concomitantly downregulating NF-κB signaling. The gene discussed is NR1I2; the disease is inflammatory bowel disease.